AstraZeneca feels the power of hope for anti-cancer drugs: after the success of the coronavirus, its share soars in study data
- AstraZeneca was the top riser on the FTSE 100 after a strong week of reporting positive clinical data for two anti-cancer drugs.
- Data published from clinical trials of Lymphalza tablets show “statistically significant and clinically significant improvement” in survival in men suffering from prostate cancer
- Prostate cancer is the most common cancer in men, and about one in eight people in the UK is diagnosed with prostate cancer in their lifetime. It is said that more than 11,500 people are killed each year.
Pharmaceutical giant AstraZeneca was the top riser on the FTSE 100 yesterday after a strong week of reporting positive clinical data for two anti-cancer drugs.
Data released yesterday from a clinical trial of Lymphalza tablets showed a “statistically significant and clinically meaningful improvement” in survival in men suffering from prostate cancer, he said.
Prostate cancer is the most common cancer in men, and about one in eight people in the UK is diagnosed with prostate cancer in their lifetime. It kills more than 11,500 people annually.
Take the initiative: CEO Pascal Soriot (pictured) took over in 2012, then focused on launching a blockbuster oncology drug and boosted stock prices
“Today, men with prostate cancer have limited options, and sadly, the disease often progresses after initial treatment with current standard treatment,” said Astra, vice president of oncology research and development. One Susan Galbraith said.
“These exciting results show that Lymphalza … may become a new first-line choice for patients and reach a broader population of patients with this invasive disease. About the results, global health as soon as possible. I look forward to discussing with the authorities. ”
Lymphalza has already been approved in several countries, including the United States and Japan, for the treatment of breast, ovarian and pancreatic cancers.
According to Jeffreys analysts, successful clinical trials can be very lucrative, with 30,000 to 50,000 patients suffering from cancer in the United States alone and sales of £ 2.2 billion to £ 3.7 billion. It states that it is an “important commercial opportunity.”
Globally, they said the drug could be worth up to £ 7.3 billion.
Shore Capital analysts said:
After taking over in 2012, CEO Pascal Soriot focused on launching a blockbuster oncology drug, raising its share price, which rose 2% (177p) yesterday, to 8845p. For Solio and the drug giant, this is his second victory in a week.
Results from a Phase III trial on Monday show that in patients with metastatic breast cancer (MBC) (also known as stage IV breast cancer), the cancer treatment reduced the risk of disease progression and death by 72%. Shown. Part of the body.
Galbraith’s results “represent a potential paradigm shift in the treatment of HER2-positive metastatic breast cancer, indicating the potential to change the lives of more patients in previous treatment environments,” Galbraith said. ..
This means that it is better at keeping patients alive without exacerbating the tumor than the drug developed by Astra’s Swiss rival Roche.
The survival rate of MBC is low, averaging about 3 years.
AstraZeneca feels the power of hope for anti-cancer drugs
https://www.dailymail.co.uk/money/markets/article-10025765/Astrazeneca-feels-force-cancer-drug-hopes.html?ns_mchannel=rss&ns_campaign=1490&ito=1490 AstraZeneca feels the power of hope for anti-cancer drugs